Graduating with a BSc in Biochemistry from the University of Sheffield, Kerry completed an AstraZeneca-funded Ph.D. from the Randall Centre for Cell and Molecular Biophysics at King’s College London, examining protein/protein interactions during cell migration.
Subsequently moving into industry, she has worked in large pharma, small biotech and CRO organisations and has significant experience in all aspects of small molecule drug discovery, primarily within the neuroscience, oncology and anti-infectives disease areas. Initially focussing on cell assay development and screening at the DNA damage response biotech, KuDOS Pharmaceuticals, she later progressed to leading drug discovery projects and managing their progress through the portfolio.
Later moving to AstraZeneca she continued to work in oncology drug discovery (DNA damage response, growth factors and metabolism). Following experience within the varied fields of anti-infectives and neuroscience, she moved to Medicines Discovery Catapult in 2017 and has worked within both the Biomarkers and Cell Model Analysis and Validation groups. Her interests are within the field of neuroinflammation, identifying biomarkers of neurodegenerative disease and building and profiling iPSC microglia cell models and assays that are more predictive of human disease.
